{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:33:56Z","timestamp":1751369636655,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s10549-024-07386-8","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T15:01:59Z","timestamp":1717599719000},"page":"551-559","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Therapeutic impact of 18F-FDG PET\/CT for initial staging in patients with clinical stage I and IIA, HER2-positive, or triple-negative breast cancer"],"prefix":"10.1007","volume":"207","author":[{"given":"Chlo\u00e9","family":"Fran\u00e7ois","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0475-8631","authenticated-orcid":false,"given":"Audrey","family":"Mailliez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Chretien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9mence","family":"Leguillette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurore","family":"Oudoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Ceugnart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u00ebl","family":"Barthoulot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Cougnenc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana\u00efs","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,5]]},"reference":[{"issue":"3","key":"7386_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ctrv.2012.04.008","volume":"39","author":"SA Hurvitz","year":"2013","unstructured":"Hurvitz SA, Hu Y, O\u2019Brien N, Finn RS (2013) Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev 39(3):219\u2013229","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"7386_CR2","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A et al (2021) ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 32(12):1475\u20131495","journal-title":"Ann Oncol"},{"issue":"6","key":"7386_CR3","doi-asserted-by":"publisher","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","volume":"20","author":"WJ Gradishar","year":"2022","unstructured":"Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH et al (2022) Breast cancer, version 3.2022, NCCN Clinical Practice Guidelines in oncology. J Nat Compr Cancer Netw 20(6):691\u2013722","journal-title":"J Nat Compr Cancer Netw"},{"key":"7386_CR4","unstructured":"Institut national du cancer (2022) Traitements locor\u00e9gionaux des cancers du sein infiltrants non m\u00e9tastatiques, Collection Recommandations et r\u00e9f\u00e9rentiels. https:\/\/e-cancer.fr. Accessed 12 Dec 2022"},{"issue":"24","key":"7386_CR5","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1093\/jnci\/djs451","volume":"104","author":"D Groheux","year":"2012","unstructured":"Groheux D, Hindi\u00e9 E, Delord M, Giacchetti S, Hamy AS, de Bazelaire C et al (2012) Prognostic impact of 18 FDG-PET-CT findings in clinical stage III and IIB breast cancer. JNCI J Nat Cancer Inst 104(24):1879\u20131887","journal-title":"JNCI J Nat Cancer Inst"},{"issue":"2","key":"7386_CR6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.2967\/jnumed.116.178749","volume":"58","author":"V Lebon","year":"2017","unstructured":"Lebon V, Alberini JL, Pierga JY, Di\u00e9ras V, Jehanno N, Wartski M (2017) Rate of distant metastases on 18F-FDG PET\/CT at initial staging of breast cancer: comparison of women younger and older than 40 years. J Nucl Med 58(2):252\u2013257","journal-title":"J Nucl Med"},{"issue":"6","key":"7386_CR7","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","volume":"17","author":"SB Edge","year":"2010","unstructured":"Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17(6):1471\u20131474","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"7386_CR8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/00129039-200109000-00012","volume":"9","author":"M Ferrero-Po\u00fcs","year":"2001","unstructured":"Ferrero-Po\u00fcs M, Trassard M, Le Doussal V, Hac\u00e8ne K, Tubiana-Hulin M, Spyratos F (2001) Comparison of enzyme immunoassay and immunohistochemical measurements of estrogen and progesterone receptors in breast cancer patients. Appl Immunohistochem Mol Morphol 9(3):267\u2013275","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"20","key":"7386_CR9","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American pathologists Clinical Practice Guideline focused update. J Clin Oncol 36(20):2105\u20132122","journal-title":"J Clin Oncol"},{"issue":"5","key":"7386_CR10","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","volume":"19","author":"CW Elston","year":"1991","unstructured":"Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403\u2013410","journal-title":"Histopathology"},{"issue":"2","key":"7386_CR11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.eururo.2018.03.030","volume":"74","author":"S Han","year":"2018","unstructured":"Han S, Woo S, Kim YJ, Suh CH (2018) Impact of 68 Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis. Eur Urol 74(2):179\u2013190","journal-title":"Eur Urol"},{"issue":"3","key":"7386_CR12","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s00259-013-2600-y","volume":"41","author":"MJ Seo","year":"2014","unstructured":"Seo MJ, Lee JJ, Kim HO, Chae SY, Park SH, Ryu JS et al (2014) Detection of internal mammary lymph node metastasis with 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in patients with stage III breast cancer. Eur J Nucl Med Mol Imaging 41(3):438\u2013445","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"7386_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/RLU.0000000000003502","volume":"46","author":"S Han","year":"2021","unstructured":"Han S, Choi JY (2021) Impact of 18F-FDG PET, PET\/CT, and PET\/MRI on staging and management as an initial staging modality in breast cancer. Clin Nucl Med 46(4):271\u2013282","journal-title":"Clin Nucl Med"},{"issue":"3","key":"7386_CR14","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s00259-013-2595-4","volume":"41","author":"A Cochet","year":"2014","unstructured":"Cochet A, Dygai-Cochet I, Riedinger JM, Humbert O, Berriolo-Riedinger A, Toubeau M et al (2014) 18F-FDG PET\/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations. Eur J Nucl Med Mol Imaging 41(3):428\u2013437","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"7386_CR15","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1097\/MNM.0000000000001466","volume":"42","author":"E Kong","year":"2021","unstructured":"Kong E, Choi J (2021) The new perspective of PET\/CT for axillary nodal staging in early breast cancer patients according to ACOSOG Z0011 trial PET\/CT axillary staging according to Z0011. Nucl Med Commun 42(12):1369\u20131374","journal-title":"Nucl Med Commun"},{"issue":"6","key":"7386_CR16","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/bjs.5338","volume":"93","author":"A Gil-Rendo","year":"2006","unstructured":"Gil-Rendo A, Zornoza G, Garc\u00eda-Velloso MJ, Regueira FM, Beorlegui C, Cervera M (2006) Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer. Br J Surg 93(6):707\u2013712","journal-title":"Br J Surg"},{"key":"7386_CR17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.radonc.2019.08.021","volume":"142","author":"KJ Borm","year":"2020","unstructured":"Borm KJ, Oechsner M, D\u00fcsberg M, Buschner G, Weber W, Combs SE et al (2020) Irradiation of regional lymph node areas in breast cancer\u2014dose evaluation according to the Z0011, AMAROS, EORTC 10981\u201322023 and MA-20 field design. Radiother Oncol 142:195\u2013201","journal-title":"Radiother Oncol"},{"issue":"3","key":"7386_CR18","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.ijrobp.2018.07.2025","volume":"103","author":"KJ Borm","year":"2019","unstructured":"Borm KJ, Voppichler J, D\u00fcsberg M, Oechsner M, Vag T, Weber W et al (2019) FDG\/PET-CT-based lymph node atlas in breast cancer patients. Int J Radiat Oncol Biol Phys 103(3):574\u2013582","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"7386_CR19","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1007\/s00330-015-3630-6","volume":"25","author":"J Krammer","year":"2015","unstructured":"Krammer J, Schnitzer A, Kaiser CG, Buesing KA, Sperk E, Brade J et al (2015) 18 F-FDG PET\/CT for initial staging in breast cancer patients\u2014Is there a relevant impact on treatment planning compared to conventional staging modalities? Eur Radiol 25(8):2460\u20132469","journal-title":"Eur Radiol"},{"issue":"11","key":"7386_CR20","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s00259-016-3402-9","volume":"43","author":"GA Ulaner","year":"2016","unstructured":"Ulaner GA, Castillo R, Goldman DA, Wills J, Riedl CC, Pinker-Domenig K et al (2016) 18F-FDG-PET\/CT for systemic staging of newly diagnosed triple-negative breast cancer. Eur J Nucl Med Mol Imaging 43(11):1937\u20131944","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"7386_CR21","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1007\/s00259-017-3709-1","volume":"44","author":"GA Ulaner","year":"2017","unstructured":"Ulaner GA, Castillo R, Wills J, G\u00f6nen M, Goldman DA (2017) 18F\u2013FDG-PET\/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer. Eur J Nucl Med Mol Imaging 44(9):1420\u20131427","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"7386_CR22","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10549-012-2179-1","volume":"135","author":"BB Koolen","year":"2012","unstructured":"Koolen BB, Vald\u00e9s Olmos RA, Elkhuizen PHM, Vogel WV, Vrancken Peeters MJTFD, Rodenhuis S et al (2012) Locoregional lymph node involvement on 18F-FDG PET\/CT in breast cancer patients scheduled for neoadjuvant chemotherapy. Breast Cancer Res Treat 135(1):231\u2013240","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"7386_CR23","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/MNM.0b013e32835f163f","volume":"34","author":"R Sebro","year":"2013","unstructured":"Sebro R, Aparici CM, Pampaloni MH (2013) Frequency and clinical implications of incidental new primary cancers detected on true whole-body 18F-FDG PET\/CT studies. Nucl Med Commun 34(4):333\u2013339","journal-title":"Nucl Med Commun"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07386-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-024-07386-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-024-07386-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T22:02:30Z","timestamp":1727128950000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-024-07386-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,5]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["7386"],"URL":"https:\/\/doi.org\/10.1007\/s10549-024-07386-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2024,6,5]]},"assertion":[{"value":"23 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Institutional Review Board of the Oscar Lambret Center has confirmed that no ethical approval is required (number CEC-2023\u2013001). The study complies with the \u201creference methodology\u201d MR004 adopted by the French Data Protection Authority (CNIL).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was waived and we verified that patients did not object to their clinical data being used for the research purposes.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Fig.\u00a0.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}